Patent Number: 7,132,408

Title: Composition and method for inhibiting platelet aggregation

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y.sub.12 receptor antagonist compound, wherein said amount is effective to bind the P2Y.sub.12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y.sub.12 receptor antagonist compounds useful for this invention include mononucleoside 5'-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5'-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5'-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.

Inventors: Boyer; Jose L. (Chapel Hill, NC), Douglass, III; James G. (Apex, NC), Shaver; Sammy R. (Chapel Hill, NC), Bednarski; Krzysztof (Raleigh, NC), Yerxa; Benjamin R. (Raleigh, NC), Olins; Gillian M. (San Diego, CA)

Assignee: Inspire Pharmaceuticals, Inc.

International Classification: A01N 43/04 (20060101); A61K 31/70 (20060101)

Expiration Date: 2019-11-07 0:00:00